Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Prognostic value of baseline metabolic tumor volume in early stage Hodgkin's lymphoma in the standard arm of H10 trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Low vs. high hemoglobin trigger for Transfusion in Vascular surgery (TV): a randomized clinical feasibility trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. A small change makes a big difference in Hodgkin lymphoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Treatment dilemmas in asymptomatic children with primary hemophagocytic lymphohistiocytosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. A small change makes a big difference in Hodgkin lymphoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Nuklearmedicinsk diagnostik og cancerpræcisionsmedicin

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Improvements in Imaging of Hodgkin Lymphoma: Positron Emission Tomography

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Anne Ségolène Cottereau
  • Annibale Versari
  • Annika Loft
  • Olivier Casasnovas
  • Monica Bellei
  • Romain Ricci
  • Stéphane Bardet
  • Antonio Castagnoli
  • Pauline Brice
  • John Raemaekers
  • Bénédicte Deau
  • Catherine Fortpied
  • Tiana Raveloarivahy
  • Emelie Van Zele
  • Loic Chartier
  • Thierry Vander Borght
  • Massimo Federico
  • Martin Hutchings
  • Umberto Ricardi
  • Marc Andre
  • Michel Meignan
Vis graf over relationer

We tested baseline PET/CT as a measure of total tumor burden in order to better identify high risk patients in early-stage Hodgkin's lymphoma (HL). Stage I-II HL patients enrolled in the standard arm (combined modality treatment) of the H10 trial (NCT00433433) with available baseline PET and interim PET (iPET2) after two cycles of doxorubicine, bleomycin, vinblastine, dacarbazine were included. Total metabolic tumor volume (TMTV) was measured on baseline PET. IPET2 findings were reported negative (DS1-3) or positive (DS4-5) with the Deauville scale. The prognostic value of TMTV was evaluated and compared to baseline characteristics, staging classifications and iPET2. A total of 258 patients were eligible, 101 favorable and 157 unfavorable. The median follow-up was 55 months, with 27 PFS and 12 OS events. TMTV was prognosticator of PFS (p<0.0001) and OS (p=0.0001) with an 86% and 84% specificity respectively. The 5y-PFS and OS were 71% and 83% in the high TMTV (>147cm3) group (n=46) vs. 92% and 98% in the low TMTV group (≤147cm3). In multivariable analysis including iPET2, TMTV was the only baseline prognosticator compared to the current staging systems proposed by EORTC/GELA, GHSG, or NCCN groups. TMTV and iPET2 were independently prognostic and combined identified four risk groups: low (TMTV≤147+DS1-3; 5y-PFS 95%), low-intermediate (TMTV>147+DS1-3; 5y-PFS 81.6%), high-intermediate (TMTV≤147+DS4-5; 5y-PFS 50%) and high (TMTV>147+DS4-5; 5y-PFS 25%). TMTV improves baseline risk stratification of early stage HL patients compared to current staging systems and the predictive value of early PET response as well.

OriginalsprogEngelsk
TidsskriftBlood
Vol/bind131
Sider (fra-til)1456-1463
ISSN0006-4971
DOI
StatusUdgivet - 1 feb. 2018

ID: 52764519